{"id":16065,"date":"2025-07-15T09:02:37","date_gmt":"2025-07-15T06:02:37","guid":{"rendered":"https:\/\/medicalpointinternational.com\/%d0%b2%d1%80%d0%b0%d1%87%d0%b8\/%d0%bf%d1%80%d0%be%d1%84%d0%b5%d1%81%d1%81%d0%be%d1%80-%d1%81%d0%b5%d1%80%d0%ba%d0%b0%d0%bd-%d0%be%d0%b7%d0%b0%d0%ba%d0%b1%d0%b0%d1%88\/"},"modified":"2026-06-22T09:28:31","modified_gmt":"2026-06-22T06:28:31","slug":"%d0%bf%d1%80%d0%be%d1%84%d0%b5%d1%81%d1%81%d0%be%d1%80-%d1%81%d0%b5%d1%80%d0%ba%d0%b0%d0%bd-%d0%be%d0%b7%d0%b0%d0%ba%d0%b1%d0%b0%d1%88","status":"publish","type":"page","link":"https:\/\/medicalpointinternational.com\/ru\/%d0%b2%d1%80%d0%b0%d1%87%d0%b8\/%d0%bf%d1%80%d0%be%d1%84%d0%b5%d1%81%d1%81%d0%be%d1%80-%d1%81%d0%b5%d1%80%d0%ba%d0%b0%d0%bd-%d0%be%d0%b7%d0%b0%d0%ba%d0%b1%d0%b0%d1%88\/","title":{"rendered":"\u041f\u0440\u043e\u0444\u0435\u0441\u0441\u043e\u0440 \u0421\u0435\u0440\u043a\u0430\u043d \u041e\u0437\u0430\u043a\u0431\u0430\u0448, \u0434\u043e\u043a\u0442\u043e\u0440 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u043d\u0430\u0443\u043a"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><div data-elementor-type=\"wp-page\" data-elementor-id=\"16065\" class=\"elementor elementor-16065 elementor-2625\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-45f980e4 e-flex e-con-boxed e-con e-parent\" data-id=\"45f980e4\" data-element_type=\"container\" data-settings='{\"background_background\":\"slideshow\",\"background_slideshow_gallery\":[{\"id\":1509,\"url\":\"https:\\\/\\\/medicalpointinternational.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/MedicalPoint-International-Hospital-About-Us-Pic.webp\"}],\"background_slideshow_loop\":\"yes\",\"background_slideshow_slide_duration\":5000,\"background_slideshow_slide_transition\":\"fade\",\"background_slideshow_transition_duration\":500}'>\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-74a70ce5 e-con-full e-flex e-con e-child\" data-id=\"74a70ce5\" data-element_type=\"container\" data-settings='{\"background_background\":\"classic\"}'>\n\t\t<div class=\"elementor-element elementor-element-5bb0b234 e-con-full e-flex e-con e-child\" data-id=\"5bb0b234\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7521995c elementor-widget elementor-widget-image\" data-id=\"7521995c\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"572\" src=\"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1024x732.jpg\" class=\"attachment-large size-large wp-image-16068\" alt=\"\" srcset=\"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1024x732.jpg 1024w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-300x214.jpg 300w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-768x549.jpg 768w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1536x1098.jpg 1536w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology.jpg 1652w\" sizes=\"(max-width: 800px) 100vw, 800px\" title=\"\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5f0e7727 e-con-full e-flex e-con e-child\" data-id=\"5f0e7727\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-36508bae elementor-widget elementor-widget-heading\" data-id=\"36508bae\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">&#1055;&#1088;&#1086;&#1092;&#1077;&#1089;&#1089;&#1086;&#1088; &#1057;&#1077;&#1088;&#1082;&#1072;&#1085; &#1054;&#1079;&#1072;&#1082;&#1073;&#1072;&#1096;, &#1076;&#1086;&#1082;&#1090;&#1086;&#1088; &#1084;&#1077;&#1076;&#1080;&#1094;&#1080;&#1085;&#1089;&#1082;&#1080;&#1093; &#1085;&#1072;&#1091;&#1082;<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-762b35a6 elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"762b35a6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<i style=\"color:#ffffff\" class=\"fas fa-map-marker-alt\"><\/i> <span>&#1041;&#1086;&#1083;&#1100;&#1085;&#1080;&#1094;&#1072; MedicalPoint Izmir<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5fcfe0e2 elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"5fcfe0e2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<span>&#1053;&#1077;&#1074;&#1088;&#1086;&#1083;&#1086;&#1075;&#1080;&#1103;<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-da0541a e-con-full e-flex e-con e-child\" data-id=\"da0541a\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-2ff01d4d e-con-full e-flex e-con e-child\" data-id=\"2ff01d4d\" data-element_type=\"container\" data-settings='{\"background_background\":\"classic\"}'>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e5c3d23 elementor-widget elementor-widget-heading\" data-id=\"4e5c3d23\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">&#1047;&#1072;&#1087;&#1088;&#1086;&#1089; &#1086;&#1073;&#1088;&#1072;&#1090;&#1085;&#1086;&#1075;&#1086; &#1079;&#1074;&#1086;&#1085;&#1082;&#1072;<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7627fcaa ekit_wpForms_container-form-button-full-width elementor-widget-mobile__width-initial elementor-widget elementor-widget-elementskit-wp-forms\" data-id=\"7627fcaa\" data-element_type=\"widget\" data-widget_type=\"elementskit-wp-forms.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con ekit_wpForms_container\"><div class=\"wpforms-container wpforms-container-full wpforms-render-modern\" id=\"wpforms-2447\"><form id=\"wpforms-form-2447\" class=\"wpforms-validate wpforms-form wpforms-ajax-form\" data-formid=\"2447\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/ru\/wp-json\/wp\/v2\/pages\/16065\" data-token=\"2435a63b5288506abe8563de299f7329\" data-token-time=\"1784008908\"><noscript class=\"wpforms-error-noscript\">&#1055;&#1086;&#1078;&#1072;&#1083;&#1091;&#1081;&#1089;&#1090;&#1072;, &#1074;&#1082;&#1083;&#1102;&#1095;&#1080;&#1090;&#1077; JavaScript &#1074; &#1042;&#1072;&#1096;&#1077;&#1084; &#1073;&#1088;&#1072;&#1091;&#1079;&#1077;&#1088;&#1077;, &#1095;&#1090;&#1086;&#1073;&#1099; &#1079;&#1072;&#1087;&#1086;&#1083;&#1085;&#1080;&#1090;&#1100; &#1101;&#1090;&#1091; &#1092;&#1086;&#1088;&#1084;&#1091;.<\/noscript><div class=\"wpforms-hidden\" id=\"wpforms-error-noscript\">&#1055;&#1086;&#1078;&#1072;&#1083;&#1091;&#1081;&#1089;&#1090;&#1072;, &#1074;&#1082;&#1083;&#1102;&#1095;&#1080;&#1090;&#1077; JavaScript &#1074; &#1042;&#1072;&#1096;&#1077;&#1084; &#1073;&#1088;&#1072;&#1091;&#1079;&#1077;&#1088;&#1077;, &#1095;&#1090;&#1086;&#1073;&#1099; &#1079;&#1072;&#1087;&#1086;&#1083;&#1085;&#1080;&#1090;&#1100; &#1101;&#1090;&#1091; &#1092;&#1086;&#1088;&#1084;&#1091;.<\/div><div class=\"wpforms-field-container\"><div id=\"wpforms-2447-field_1-container\" class=\"wpforms-field wpforms-field-name\" data-field-id=\"1\"><fieldset><legend class=\"wpforms-field-label wpforms-label-hide\" aria-hidden=\"false\">&#1048;&#1084;&#1103; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/legend><div class=\"wpforms-field-row wpforms-field-large\"><div class=\"wpforms-field-row-block wpforms-first wpforms-one-half\"><input type=\"text\" id=\"wpforms-2447-field_1\" class=\"wpforms-field-name-first wpforms-field-required\" name=\"wpforms[fields][1][first]\" placeholder=\"&#1048;&#1084;&#1103;\" aria-errormessage=\"wpforms-2447-field_1-error\" required><label for=\"wpforms-2447-field_1\" class=\"wpforms-field-sublabel after wpforms-sublabel-hide\">&#1055;&#1077;&#1088;&#1074;&#1099;&#1081;<\/label><\/div><div class=\"wpforms-field-row-block wpforms-one-half\"><input type=\"text\" id=\"wpforms-2447-field_1-last\" class=\"wpforms-field-name-last wpforms-field-required\" name=\"wpforms[fields][1][last]\" placeholder=\"&#1060;&#1072;&#1084;&#1080;&#1083;&#1080;&#1103;\" aria-errormessage=\"wpforms-2447-field_1-last-error\" required><label for=\"wpforms-2447-field_1-last\" class=\"wpforms-field-sublabel after wpforms-sublabel-hide\">&#1055;&#1086;&#1089;&#1083;&#1077;&#1076;&#1085;&#1080;&#1081;<\/label><\/div><\/div><\/fieldset><\/div><div id=\"wpforms-2447-field_2-container\" class=\"wpforms-field wpforms-field-phone\" data-field-id=\"2\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_2\" aria-hidden=\"false\">&#1058;&#1077;&#1083;&#1077;&#1092;&#1086;&#1085; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"tel\" id=\"wpforms-2447-field_2\" class=\"wpforms-field-large wpforms-field-required wpforms-smart-phone-field\" data-rule-smart-phone-field=\"true\" name=\"wpforms[fields][2]\" placeholder=\"&#1058;&#1077;&#1083;&#1077;&#1092;&#1086;&#1085;\" aria-label=\"&#1058;&#1077;&#1083;&#1077;&#1092;&#1086;&#1085;\" aria-errormessage=\"wpforms-2447-field_2-error\" required><\/div><div id=\"wpforms-2447-field_4-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"4\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_4\" aria-hidden=\"false\">&#1069;&#1083;&#1077;&#1082;&#1090;&#1088;&#1086;&#1085;&#1085;&#1072;&#1103; &#1087;&#1086;&#1095;&#1090;&#1072; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"email\" id=\"wpforms-2447-field_4\" class=\"wpforms-field-large wpforms-field-required\" name=\"wpforms[fields][4]\" placeholder=\"&#1069;&#1083;&#1077;&#1082;&#1090;&#1088;&#1086;&#1085;&#1085;&#1072;&#1103; &#1087;&#1086;&#1095;&#1090;&#1072;\" spellcheck=\"false\" aria-errormessage=\"wpforms-2447-field_4-error\" required><\/div><div id=\"wpforms-2447-field_7-container\" class=\"wpforms-field wpforms-field-select wpforms-field-select-style-modern\" data-field-id=\"7\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_7\" aria-hidden=\"false\">&#1057;&#1090;&#1088;&#1072;&#1085;&#1072; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><select id=\"wpforms-2447-field_7\" class=\"wpforms-field-large wpforms-field-required choicesjs-select\" data-size-class=\"wpforms-field-row wpforms-field-large\" data-search-enabled=\"1\" name=\"wpforms[fields][7]\" required=\"required\"><option value=\"\" class=\"placeholder\" disabled selected>&#1057;&#1090;&#1088;&#1072;&#1085;&#1072;<\/option><option value=\"&#1040;&#1092;&#1075;&#1072;&#1085;&#1080;&#1089;&#1090;&#1072;&#1085;\">&#1040;&#1092;&#1075;&#1072;&#1085;&#1080;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1040;&#1083;&#1073;&#1072;&#1085;&#1080;&#1103;\">&#1040;&#1083;&#1073;&#1072;&#1085;&#1080;&#1103;<\/option><option value=\"&#1040;&#1083;&#1078;&#1080;&#1088;\">&#1040;&#1083;&#1078;&#1080;&#1088;<\/option><option value=\"&#1040;&#1085;&#1076;&#1086;&#1088;&#1088;&#1072;\">&#1040;&#1085;&#1076;&#1086;&#1088;&#1088;&#1072;<\/option><option value=\"&#1040;&#1085;&#1075;&#1086;&#1083;&#1072;\">&#1040;&#1085;&#1075;&#1086;&#1083;&#1072;<\/option><option value=\"&#1040;&#1085;&#1090;&#1080;&#1075;&#1091;&#1072; &#1080; &#1041;&#1072;&#1088;&#1073;&#1091;&#1076;&#1072;\">&#1040;&#1085;&#1090;&#1080;&#1075;&#1091;&#1072; &#1080; &#1041;&#1072;&#1088;&#1073;&#1091;&#1076;&#1072;<\/option><option value=\"&#1040;&#1088;&#1075;&#1077;&#1085;&#1090;&#1080;&#1085;&#1072;\">&#1040;&#1088;&#1075;&#1077;&#1085;&#1090;&#1080;&#1085;&#1072;<\/option><option value=\"&#1040;&#1088;&#1084;&#1077;&#1085;&#1080;&#1103;\">&#1040;&#1088;&#1084;&#1077;&#1085;&#1080;&#1103;<\/option><option value=\"&#1040;&#1074;&#1089;&#1090;&#1088;&#1072;&#1083;&#1080;&#1103;\">&#1040;&#1074;&#1089;&#1090;&#1088;&#1072;&#1083;&#1080;&#1103;<\/option><option value=\"&#1040;&#1074;&#1089;&#1090;&#1088;&#1080;&#1103;\">&#1040;&#1074;&#1089;&#1090;&#1088;&#1080;&#1103;<\/option><option value=\"&#1040;&#1079;&#1077;&#1088;&#1073;&#1072;&#1081;&#1076;&#1078;&#1072;&#1085;\">&#1040;&#1079;&#1077;&#1088;&#1073;&#1072;&#1081;&#1076;&#1078;&#1072;&#1085;<\/option><option value=\"&#1041;&#1072;&#1075;&#1072;&#1084;&#1099;\">&#1041;&#1072;&#1075;&#1072;&#1084;&#1099;<\/option><option value=\"&#1041;&#1072;&#1093;&#1088;&#1077;&#1081;&#1085;\">&#1041;&#1072;&#1093;&#1088;&#1077;&#1081;&#1085;<\/option><option value=\"&#1041;&#1072;&#1085;&#1075;&#1083;&#1072;&#1076;&#1077;&#1096;\">&#1041;&#1072;&#1085;&#1075;&#1083;&#1072;&#1076;&#1077;&#1096;<\/option><option value=\"&#1041;&#1072;&#1088;&#1073;&#1072;&#1076;&#1086;&#1089;\">&#1041;&#1072;&#1088;&#1073;&#1072;&#1076;&#1086;&#1089;<\/option><option value=\"&#1041;&#1077;&#1083;&#1072;&#1088;&#1091;&#1089;&#1100;\">&#1041;&#1077;&#1083;&#1072;&#1088;&#1091;&#1089;&#1100;<\/option><option value=\"&#1041;&#1077;&#1083;&#1100;&#1075;&#1080;&#1103;\">&#1041;&#1077;&#1083;&#1100;&#1075;&#1080;&#1103;<\/option><option value=\"&#1041;&#1077;&#1083;&#1080;&#1079;\">&#1041;&#1077;&#1083;&#1080;&#1079;<\/option><option value=\"&#1041;&#1077;&#1085;&#1080;&#1085;\">&#1041;&#1077;&#1085;&#1080;&#1085;<\/option><option value=\"&#1041;&#1091;&#1090;&#1072;&#1085;\">&#1041;&#1091;&#1090;&#1072;&#1085;<\/option><option value=\"&#1041;&#1086;&#1083;&#1080;&#1074;&#1080;&#1103;\">&#1041;&#1086;&#1083;&#1080;&#1074;&#1080;&#1103;<\/option><option value=\"&#1041;&#1086;&#1089;&#1085;&#1080;&#1103; &#1080; &#1043;&#1077;&#1088;&#1094;&#1077;&#1075;&#1086;&#1074;&#1080;&#1085;&#1072;\">&#1041;&#1086;&#1089;&#1085;&#1080;&#1103; &#1080; &#1043;&#1077;&#1088;&#1094;&#1077;&#1075;&#1086;&#1074;&#1080;&#1085;&#1072;<\/option><option value=\"&#1041;&#1086;&#1090;&#1089;&#1074;&#1072;&#1085;&#1072;\">&#1041;&#1086;&#1090;&#1089;&#1074;&#1072;&#1085;&#1072;<\/option><option value=\"&#1041;&#1088;&#1072;&#1079;&#1080;&#1083;&#1080;&#1103;\">&#1041;&#1088;&#1072;&#1079;&#1080;&#1083;&#1080;&#1103;<\/option><option value=\"&#1041;&#1088;&#1091;&#1085;&#1077;&#1081;\">&#1041;&#1088;&#1091;&#1085;&#1077;&#1081;<\/option><option value=\"&#1041;&#1086;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;\">&#1041;&#1086;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;<\/option><option value=\"&#1041;&#1091;&#1088;&#1082;&#1080;&#1085;&#1072;-&#1060;&#1072;&#1089;&#1086;\">&#1041;&#1091;&#1088;&#1082;&#1080;&#1085;&#1072;-&#1060;&#1072;&#1089;&#1086;<\/option><option value=\"&#1041;&#1091;&#1088;&#1091;&#1085;&#1076;&#1080;\">&#1041;&#1091;&#1088;&#1091;&#1085;&#1076;&#1080;<\/option><option value=\"&#1050;&#1072;&#1073;&#1086;-&#1042;&#1077;&#1088;&#1076;&#1077;\">&#1050;&#1072;&#1073;&#1086;-&#1042;&#1077;&#1088;&#1076;&#1077;<\/option><option value=\"&#1050;&#1072;&#1084;&#1073;&#1086;&#1076;&#1078;&#1072;\">&#1050;&#1072;&#1084;&#1073;&#1086;&#1076;&#1078;&#1072;<\/option><option value=\"&#1050;&#1072;&#1084;&#1077;&#1088;&#1091;&#1085;\">&#1050;&#1072;&#1084;&#1077;&#1088;&#1091;&#1085;<\/option><option value=\"&#1050;&#1072;&#1085;&#1072;&#1076;&#1072;\">&#1050;&#1072;&#1085;&#1072;&#1076;&#1072;<\/option><option value=\"&#1062;&#1077;&#1085;&#1090;&#1088;&#1072;&#1083;&#1100;&#1085;&#1086;&#1072;&#1092;&#1088;&#1080;&#1082;&#1072;&#1085;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;\">&#1062;&#1077;&#1085;&#1090;&#1088;&#1072;&#1083;&#1100;&#1085;&#1086;&#1072;&#1092;&#1088;&#1080;&#1082;&#1072;&#1085;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;<\/option><option value=\"&#1063;&#1072;&#1076;\">&#1063;&#1072;&#1076;<\/option><option value=\"&#1063;&#1080;&#1083;&#1080;\">&#1063;&#1080;&#1083;&#1080;<\/option><option value=\"&#1050;&#1080;&#1090;&#1072;&#1081;\">&#1050;&#1080;&#1090;&#1072;&#1081;<\/option><option value=\"&#1050;&#1086;&#1083;&#1091;&#1084;&#1073;&#1080;&#1103;\">&#1050;&#1086;&#1083;&#1091;&#1084;&#1073;&#1080;&#1103;<\/option><option value=\"&#1050;&#1086;&#1084;&#1086;&#1088;&#1089;&#1082;&#1080;&#1077; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;\">&#1050;&#1086;&#1084;&#1086;&#1088;&#1089;&#1082;&#1080;&#1077; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;<\/option><option value=\"&#1050;&#1086;&#1085;&#1075;&#1086;, &#1044;&#1077;&#1084;&#1086;&#1082;&#1088;&#1072;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;\">&#1050;&#1086;&#1085;&#1075;&#1086;, &#1044;&#1077;&#1084;&#1086;&#1082;&#1088;&#1072;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;<\/option><option value=\"&#1050;&#1086;&#1085;&#1075;&#1086;, &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;\">&#1050;&#1086;&#1085;&#1075;&#1086;, &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;<\/option><option value=\"&#1050;&#1086;&#1089;&#1090;&#1072;-&#1056;&#1080;&#1082;&#1072;\">&#1050;&#1086;&#1089;&#1090;&#1072;-&#1056;&#1080;&#1082;&#1072;<\/option><option value=\"&#1050;&#1086;&#1090;-&#1076;'&#1048;&#1074;&#1091;&#1072;&#1088;\">&#1050;&#1086;&#1090;-&#1076;'&#1048;&#1074;&#1091;&#1072;&#1088;<\/option><option value=\"&#1061;&#1086;&#1088;&#1074;&#1072;&#1090;&#1080;&#1103;\">&#1061;&#1086;&#1088;&#1074;&#1072;&#1090;&#1080;&#1103;<\/option><option value=\"&#1050;&#1091;&#1073;&#1072;\">&#1050;&#1091;&#1073;&#1072;<\/option><option value=\"&#1050;&#1080;&#1087;&#1088;\">&#1050;&#1080;&#1087;&#1088;<\/option><option value=\"&#1063;&#1077;&#1096;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;\">&#1063;&#1077;&#1096;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;<\/option><option value=\"&#1044;&#1072;&#1085;&#1080;&#1103;\">&#1044;&#1072;&#1085;&#1080;&#1103;<\/option><option value=\"&#1044;&#1078;&#1080;&#1073;&#1091;&#1090;&#1080;\">&#1044;&#1078;&#1080;&#1073;&#1091;&#1090;&#1080;<\/option><option value=\"&#1044;&#1086;&#1084;&#1080;&#1085;&#1080;&#1082;&#1072;\">&#1044;&#1086;&#1084;&#1080;&#1085;&#1080;&#1082;&#1072;<\/option><option value=\"&#1044;&#1086;&#1084;&#1080;&#1085;&#1080;&#1082;&#1072;&#1085;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;\">&#1044;&#1086;&#1084;&#1080;&#1085;&#1080;&#1082;&#1072;&#1085;&#1089;&#1082;&#1072;&#1103; &#1056;&#1077;&#1089;&#1087;&#1091;&#1073;&#1083;&#1080;&#1082;&#1072;<\/option><option value=\"&#1042;&#1086;&#1089;&#1090;&#1086;&#1095;&#1085;&#1099;&#1081; &#1058;&#1080;&#1084;&#1086;&#1088; (&#1058;&#1080;&#1084;&#1086;&#1088;-&#1051;&#1077;&#1096;&#1090;&#1080;)\">&#1042;&#1086;&#1089;&#1090;&#1086;&#1095;&#1085;&#1099;&#1081; &#1058;&#1080;&#1084;&#1086;&#1088; (&#1058;&#1080;&#1084;&#1086;&#1088;-&#1051;&#1077;&#1096;&#1090;&#1080;)<\/option><option value=\"&#1069;&#1082;&#1074;&#1072;&#1076;&#1086;&#1088;\">&#1069;&#1082;&#1074;&#1072;&#1076;&#1086;&#1088;<\/option><option value=\"&#1045;&#1075;&#1080;&#1087;&#1077;&#1090;\">&#1045;&#1075;&#1080;&#1087;&#1077;&#1090;<\/option><option value=\"&#1057;&#1072;&#1083;&#1100;&#1074;&#1072;&#1076;&#1086;&#1088;\">&#1057;&#1072;&#1083;&#1100;&#1074;&#1072;&#1076;&#1086;&#1088;<\/option><option value=\"&#1069;&#1082;&#1074;&#1072;&#1090;&#1086;&#1088;&#1080;&#1072;&#1083;&#1100;&#1085;&#1072;&#1103; &#1043;&#1074;&#1080;&#1085;&#1077;&#1103;\">&#1069;&#1082;&#1074;&#1072;&#1090;&#1086;&#1088;&#1080;&#1072;&#1083;&#1100;&#1085;&#1072;&#1103; &#1043;&#1074;&#1080;&#1085;&#1077;&#1103;<\/option><option value=\"&#1069;&#1088;&#1080;&#1090;&#1088;&#1077;&#1103;\">&#1069;&#1088;&#1080;&#1090;&#1088;&#1077;&#1103;<\/option><option value=\"&#1069;&#1089;&#1090;&#1086;&#1085;&#1080;&#1103;\">&#1069;&#1089;&#1090;&#1086;&#1085;&#1080;&#1103;<\/option><option value=\"&#1069;&#1089;&#1074;&#1072;&#1090;&#1080;&#1085;&#1080;\">&#1069;&#1089;&#1074;&#1072;&#1090;&#1080;&#1085;&#1080;<\/option><option value=\"&#1069;&#1092;&#1080;&#1086;&#1087;&#1080;&#1103;\">&#1069;&#1092;&#1080;&#1086;&#1087;&#1080;&#1103;<\/option><option value=\"&#1060;&#1080;&#1076;&#1078;&#1080;\">&#1060;&#1080;&#1076;&#1078;&#1080;<\/option><option value=\"&#1060;&#1080;&#1085;&#1083;&#1103;&#1085;&#1076;&#1080;&#1103;\">&#1060;&#1080;&#1085;&#1083;&#1103;&#1085;&#1076;&#1080;&#1103;<\/option><option value=\"&#1060;&#1088;&#1072;&#1085;&#1094;&#1080;&#1103;\">&#1060;&#1088;&#1072;&#1085;&#1094;&#1080;&#1103;<\/option><option value=\"&#1043;&#1072;&#1085;&#1072;\">&#1043;&#1072;&#1085;&#1072;<\/option><option value=\"&#1043;&#1088;&#1077;&#1094;&#1080;&#1103;\">&#1043;&#1088;&#1077;&#1094;&#1080;&#1103;<\/option><option value=\"&#1043;&#1088;&#1077;&#1085;&#1072;&#1076;&#1072;\">&#1043;&#1088;&#1077;&#1085;&#1072;&#1076;&#1072;<\/option><option value=\"&#1043;&#1074;&#1072;&#1090;&#1077;&#1084;&#1072;&#1083;&#1072;\">&#1043;&#1074;&#1072;&#1090;&#1077;&#1084;&#1072;&#1083;&#1072;<\/option><option value=\"&#1043;&#1074;&#1080;&#1085;&#1077;&#1103;\">&#1043;&#1074;&#1080;&#1085;&#1077;&#1103;<\/option><option value=\"&#1043;&#1074;&#1080;&#1085;&#1077;&#1103;-&#1041;&#1080;&#1089;&#1072;&#1091;\">&#1043;&#1074;&#1080;&#1085;&#1077;&#1103;-&#1041;&#1080;&#1089;&#1072;&#1091;<\/option><option value=\"&#1043;&#1072;&#1081;&#1072;&#1085;&#1072;\">&#1043;&#1072;&#1081;&#1072;&#1085;&#1072;<\/option><option value=\"&#1043;&#1072;&#1080;&#1090;&#1080;\">&#1043;&#1072;&#1080;&#1090;&#1080;<\/option><option value=\"&#1043;&#1086;&#1085;&#1076;&#1091;&#1088;&#1072;&#1089;\">&#1043;&#1086;&#1085;&#1076;&#1091;&#1088;&#1072;&#1089;<\/option><option value=\"&#1042;&#1077;&#1085;&#1075;&#1088;&#1080;&#1103;\">&#1042;&#1077;&#1085;&#1075;&#1088;&#1080;&#1103;<\/option><option value=\"&#1048;&#1089;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;\">&#1048;&#1089;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;<\/option><option value=\"&#1048;&#1085;&#1076;&#1080;&#1103;\">&#1048;&#1085;&#1076;&#1080;&#1103;<\/option><option value=\"&#1048;&#1085;&#1076;&#1086;&#1085;&#1077;&#1079;&#1080;&#1103;\">&#1048;&#1085;&#1076;&#1086;&#1085;&#1077;&#1079;&#1080;&#1103;<\/option><option value=\"&#1048;&#1088;&#1072;&#1085;\">&#1048;&#1088;&#1072;&#1085;<\/option><option value=\"&#1048;&#1088;&#1072;&#1082;\">&#1048;&#1088;&#1072;&#1082;<\/option><option value=\"&#1048;&#1088;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;\">&#1048;&#1088;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;<\/option><option value=\"&#1048;&#1079;&#1088;&#1072;&#1080;&#1083;&#1100;\">&#1048;&#1079;&#1088;&#1072;&#1080;&#1083;&#1100;<\/option><option value=\"&#1048;&#1090;&#1072;&#1083;&#1080;&#1103;\">&#1048;&#1090;&#1072;&#1083;&#1080;&#1103;<\/option><option value=\"&#1071;&#1084;&#1072;&#1081;&#1082;&#1072;\">&#1071;&#1084;&#1072;&#1081;&#1082;&#1072;<\/option><option value=\"&#1071;&#1087;&#1086;&#1085;&#1080;&#1103;\">&#1071;&#1087;&#1086;&#1085;&#1080;&#1103;<\/option><option value=\"&#1050;&#1072;&#1079;&#1072;&#1093;&#1089;&#1090;&#1072;&#1085;\">&#1050;&#1072;&#1079;&#1072;&#1093;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1050;&#1077;&#1085;&#1080;&#1103;\">&#1050;&#1077;&#1085;&#1080;&#1103;<\/option><option value=\"&#1050;&#1080;&#1088;&#1080;&#1073;&#1072;&#1090;&#1080;\">&#1050;&#1080;&#1088;&#1080;&#1073;&#1072;&#1090;&#1080;<\/option><option value=\"&#1050;&#1086;&#1088;&#1077;&#1103;, &#1057;&#1077;&#1074;&#1077;&#1088;&#1085;&#1072;&#1103;\">&#1050;&#1086;&#1088;&#1077;&#1103;, &#1057;&#1077;&#1074;&#1077;&#1088;&#1085;&#1072;&#1103;<\/option><option value=\"&#1050;&#1086;&#1088;&#1077;&#1103;, &#1070;&#1078;&#1085;&#1072;&#1103;\">&#1050;&#1086;&#1088;&#1077;&#1103;, &#1070;&#1078;&#1085;&#1072;&#1103;<\/option><option value=\"&#1050;&#1086;&#1089;&#1086;&#1074;&#1086;\">&#1050;&#1086;&#1089;&#1086;&#1074;&#1086;<\/option><option value=\"&#1050;&#1091;&#1074;&#1077;&#1081;&#1090;\">&#1050;&#1091;&#1074;&#1077;&#1081;&#1090;<\/option><option value=\"&#1050;&#1099;&#1088;&#1075;&#1099;&#1079;&#1089;&#1090;&#1072;&#1085;\">&#1050;&#1099;&#1088;&#1075;&#1099;&#1079;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1051;&#1072;&#1086;&#1089;\">&#1051;&#1072;&#1086;&#1089;<\/option><option value=\"&#1051;&#1072;&#1090;&#1074;&#1080;&#1103;\">&#1051;&#1072;&#1090;&#1074;&#1080;&#1103;<\/option><option value=\"&#1051;&#1080;&#1074;&#1072;&#1085;\">&#1051;&#1080;&#1074;&#1072;&#1085;<\/option><option value=\"&#1051;&#1077;&#1089;&#1086;&#1090;&#1086;\">&#1051;&#1077;&#1089;&#1086;&#1090;&#1086;<\/option><option value=\"&#1051;&#1080;&#1093;&#1090;&#1077;&#1085;&#1096;&#1090;&#1077;&#1081;&#1085;\">&#1051;&#1080;&#1093;&#1090;&#1077;&#1085;&#1096;&#1090;&#1077;&#1081;&#1085;<\/option><option value=\"&#1051;&#1080;&#1090;&#1074;&#1072;\">&#1051;&#1080;&#1090;&#1074;&#1072;<\/option><option value=\"&#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;\">&#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;<\/option><option value=\"&#1052;&#1072;&#1076;&#1072;&#1075;&#1072;&#1089;&#1082;&#1072;&#1088;\">&#1052;&#1072;&#1076;&#1072;&#1075;&#1072;&#1089;&#1082;&#1072;&#1088;<\/option><option value=\"&#1052;&#1072;&#1083;&#1072;&#1074;&#1080;\">&#1052;&#1072;&#1083;&#1072;&#1074;&#1080;<\/option><option value=\"&#1052;&#1072;&#1083;&#1072;&#1081;&#1079;&#1080;&#1103;\">&#1052;&#1072;&#1083;&#1072;&#1081;&#1079;&#1080;&#1103;<\/option><option value=\"&#1052;&#1072;&#1083;&#1100;&#1076;&#1080;&#1074;&#1099;\">&#1052;&#1072;&#1083;&#1100;&#1076;&#1080;&#1074;&#1099;<\/option><option value=\"&#1052;&#1072;&#1083;&#1080;\">&#1052;&#1072;&#1083;&#1080;<\/option><option value=\"&#1052;&#1072;&#1083;&#1100;&#1090;&#1072;\">&#1052;&#1072;&#1083;&#1100;&#1090;&#1072;<\/option><option value=\"&#1052;&#1072;&#1074;&#1088;&#1080;&#1082;&#1080;&#1081;\">&#1052;&#1072;&#1074;&#1088;&#1080;&#1082;&#1080;&#1081;<\/option><option value=\"&#1052;&#1077;&#1082;&#1089;&#1080;&#1082;&#1072;\">&#1052;&#1077;&#1082;&#1089;&#1080;&#1082;&#1072;<\/option><option value=\"&#1052;&#1080;&#1082;&#1088;&#1086;&#1085;&#1077;&#1079;&#1080;&#1103;, &#1060;&#1077;&#1076;&#1077;&#1088;&#1072;&#1090;&#1080;&#1074;&#1085;&#1099;&#1077; &#1064;&#1090;&#1072;&#1090;&#1099;\">&#1052;&#1080;&#1082;&#1088;&#1086;&#1085;&#1077;&#1079;&#1080;&#1103;, &#1060;&#1077;&#1076;&#1077;&#1088;&#1072;&#1090;&#1080;&#1074;&#1085;&#1099;&#1077; &#1064;&#1090;&#1072;&#1090;&#1099;<\/option><option value=\"&#1052;&#1086;&#1083;&#1076;&#1086;&#1074;&#1072;\">&#1052;&#1086;&#1083;&#1076;&#1086;&#1074;&#1072;<\/option><option value=\"&#1052;&#1086;&#1085;&#1072;&#1082;&#1086;\">&#1052;&#1086;&#1085;&#1072;&#1082;&#1086;<\/option><option value=\"&#1052;&#1086;&#1085;&#1075;&#1086;&#1083;&#1080;&#1103;\">&#1052;&#1086;&#1085;&#1075;&#1086;&#1083;&#1080;&#1103;<\/option><option value=\"&#1063;&#1077;&#1088;&#1085;&#1086;&#1075;&#1086;&#1088;&#1080;&#1103;\">&#1063;&#1077;&#1088;&#1085;&#1086;&#1075;&#1086;&#1088;&#1080;&#1103;<\/option><option value=\"&#1052;&#1072;&#1088;&#1086;&#1082;&#1082;&#1086;\">&#1052;&#1072;&#1088;&#1086;&#1082;&#1082;&#1086;<\/option><option value=\"&#1052;&#1086;&#1079;&#1072;&#1084;&#1073;&#1080;&#1082;\">&#1052;&#1086;&#1079;&#1072;&#1084;&#1073;&#1080;&#1082;<\/option><option value=\"&#1052;&#1100;&#1103;&#1085;&#1084;&#1072; (&#1041;&#1080;&#1088;&#1084;&#1072;)\">&#1052;&#1100;&#1103;&#1085;&#1084;&#1072; (&#1041;&#1080;&#1088;&#1084;&#1072;)<\/option><option value=\"&#1053;&#1072;&#1084;&#1080;&#1073;&#1080;&#1103;\">&#1053;&#1072;&#1084;&#1080;&#1073;&#1080;&#1103;<\/option><option value=\"&#1053;&#1072;&#1091;&#1088;&#1091;\">&#1053;&#1072;&#1091;&#1088;&#1091;<\/option><option value=\"&#1053;&#1077;&#1087;&#1072;&#1083;\">&#1053;&#1077;&#1087;&#1072;&#1083;<\/option><option value=\"&#1053;&#1080;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&#1099;\">&#1053;&#1080;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&#1099;<\/option><option value=\"&#1053;&#1086;&#1074;&#1072;&#1103; &#1047;&#1077;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;\">&#1053;&#1086;&#1074;&#1072;&#1103; &#1047;&#1077;&#1083;&#1072;&#1085;&#1076;&#1080;&#1103;<\/option><option value=\"&#1053;&#1080;&#1082;&#1072;&#1088;&#1072;&#1075;&#1091;&#1072;\">&#1053;&#1080;&#1082;&#1072;&#1088;&#1072;&#1075;&#1091;&#1072;<\/option><option value=\"&#1053;&#1080;&#1075;&#1077;&#1088;\">&#1053;&#1080;&#1075;&#1077;&#1088;<\/option><option value=\"&#1053;&#1080;&#1075;&#1077;&#1088;&#1080;&#1103;\">&#1053;&#1080;&#1075;&#1077;&#1088;&#1080;&#1103;<\/option><option value=\"&#1057;&#1077;&#1074;&#1077;&#1088;&#1085;&#1072;&#1103; &#1052;&#1072;&#1082;&#1077;&#1076;&#1086;&#1085;&#1080;&#1103;\">&#1057;&#1077;&#1074;&#1077;&#1088;&#1085;&#1072;&#1103; &#1052;&#1072;&#1082;&#1077;&#1076;&#1086;&#1085;&#1080;&#1103;<\/option><option value=\"&#1053;&#1086;&#1088;&#1074;&#1077;&#1075;&#1080;&#1103;\">&#1053;&#1086;&#1088;&#1074;&#1077;&#1075;&#1080;&#1103;<\/option><option value=\"&#1054;&#1084;&#1072;&#1085;\">&#1054;&#1084;&#1072;&#1085;<\/option><option value=\"&#1055;&#1072;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;\">&#1055;&#1072;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1055;&#1072;&#1083;&#1072;&#1091;\">&#1055;&#1072;&#1083;&#1072;&#1091;<\/option><option value=\"&#1055;&#1072;&#1085;&#1072;&#1084;&#1072;\">&#1055;&#1072;&#1085;&#1072;&#1084;&#1072;<\/option><option value=\"&#1055;&#1072;&#1087;&#1091;&#1072;-&#1053;&#1086;&#1074;&#1072;&#1103; &#1043;&#1074;&#1080;&#1085;&#1077;&#1103;\">&#1055;&#1072;&#1087;&#1091;&#1072;-&#1053;&#1086;&#1074;&#1072;&#1103; &#1043;&#1074;&#1080;&#1085;&#1077;&#1103;<\/option><option value=\"&#1055;&#1072;&#1088;&#1072;&#1075;&#1074;&#1072;&#1081;\">&#1055;&#1072;&#1088;&#1072;&#1075;&#1074;&#1072;&#1081;<\/option><option value=\"&#1055;&#1077;&#1088;&#1091;\">&#1055;&#1077;&#1088;&#1091;<\/option><option value=\"&#1060;&#1080;&#1083;&#1080;&#1087;&#1087;&#1080;&#1085;&#1099;\">&#1060;&#1080;&#1083;&#1080;&#1087;&#1087;&#1080;&#1085;&#1099;<\/option><option value=\"&#1055;&#1086;&#1083;&#1100;&#1096;&#1072;\">&#1055;&#1086;&#1083;&#1100;&#1096;&#1072;<\/option><option value=\"&#1055;&#1086;&#1088;&#1090;&#1091;&#1075;&#1072;&#1083;&#1080;&#1103;\">&#1055;&#1086;&#1088;&#1090;&#1091;&#1075;&#1072;&#1083;&#1080;&#1103;<\/option><option value=\"&#1050;&#1072;&#1090;&#1072;&#1088;\">&#1050;&#1072;&#1090;&#1072;&#1088;<\/option><option value=\"&#1056;&#1091;&#1084;&#1099;&#1085;&#1080;&#1103;\">&#1056;&#1091;&#1084;&#1099;&#1085;&#1080;&#1103;<\/option><option value=\"&#1056;&#1086;&#1089;&#1089;&#1080;&#1103;\">&#1056;&#1086;&#1089;&#1089;&#1080;&#1103;<\/option><option value=\"&#1056;&#1091;&#1072;&#1085;&#1076;&#1072;\">&#1056;&#1091;&#1072;&#1085;&#1076;&#1072;<\/option><option value=\"&#1057;&#1077;&#1085;&#1090;-&#1050;&#1080;&#1090;&#1089; &#1080; &#1053;&#1077;&#1074;&#1080;&#1089;\">&#1057;&#1077;&#1085;&#1090;-&#1050;&#1080;&#1090;&#1089; &#1080; &#1053;&#1077;&#1074;&#1080;&#1089;<\/option><option value=\"&#1057;&#1077;&#1085;&#1090;-&#1051;&#1102;&#1089;&#1080;&#1103;\">&#1057;&#1077;&#1085;&#1090;-&#1051;&#1102;&#1089;&#1080;&#1103;<\/option><option value=\"&#1057;&#1077;&#1085;&#1090;-&#1042;&#1080;&#1085;&#1089;&#1077;&#1085;&#1090; &#1080; &#1043;&#1088;&#1077;&#1085;&#1072;&#1076;&#1080;&#1085;&#1099;\">&#1057;&#1077;&#1085;&#1090;-&#1042;&#1080;&#1085;&#1089;&#1077;&#1085;&#1090; &#1080; &#1043;&#1088;&#1077;&#1085;&#1072;&#1076;&#1080;&#1085;&#1099;<\/option><option value=\"&#1057;&#1072;&#1084;&#1086;&#1072;\">&#1057;&#1072;&#1084;&#1086;&#1072;<\/option><option value=\"&#1057;&#1072;&#1085;-&#1052;&#1072;&#1088;&#1080;&#1085;&#1086;\">&#1057;&#1072;&#1085;-&#1052;&#1072;&#1088;&#1080;&#1085;&#1086;<\/option><option value=\"&#1057;&#1072;&#1085;-&#1058;&#1086;&#1084;&#1077; &#1080; &#1055;&#1088;&#1080;&#1085;&#1089;&#1080;&#1087;&#1080;\">&#1057;&#1072;&#1085;-&#1058;&#1086;&#1084;&#1077; &#1080; &#1055;&#1088;&#1080;&#1085;&#1089;&#1080;&#1087;&#1080;<\/option><option value=\"&#1057;&#1072;&#1091;&#1076;&#1086;&#1074;&#1089;&#1082;&#1072;&#1103; &#1040;&#1088;&#1072;&#1074;&#1080;&#1103;\">&#1057;&#1072;&#1091;&#1076;&#1086;&#1074;&#1089;&#1082;&#1072;&#1103; &#1040;&#1088;&#1072;&#1074;&#1080;&#1103;<\/option><option value=\"&#1057;&#1077;&#1085;&#1077;&#1075;&#1072;&#1083;\">&#1057;&#1077;&#1085;&#1077;&#1075;&#1072;&#1083;<\/option><option value=\"&#1057;&#1077;&#1088;&#1073;&#1080;&#1103;\">&#1057;&#1077;&#1088;&#1073;&#1080;&#1103;<\/option><option value=\"&#1057;&#1077;&#1081;&#1096;&#1077;&#1083;&#1100;&#1089;&#1082;&#1080;&#1077; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;\">&#1057;&#1077;&#1081;&#1096;&#1077;&#1083;&#1100;&#1089;&#1082;&#1080;&#1077; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;<\/option><option value=\"&#1057;&#1100;&#1077;&#1088;&#1088;&#1072;-&#1051;&#1077;&#1086;&#1085;&#1077;\">&#1057;&#1100;&#1077;&#1088;&#1088;&#1072;-&#1051;&#1077;&#1086;&#1085;&#1077;<\/option><option value=\"&#1057;&#1080;&#1085;&#1075;&#1072;&#1087;&#1091;&#1088;\">&#1057;&#1080;&#1085;&#1075;&#1072;&#1087;&#1091;&#1088;<\/option><option value=\"&#1057;&#1083;&#1086;&#1074;&#1072;&#1082;&#1080;&#1103;\">&#1057;&#1083;&#1086;&#1074;&#1072;&#1082;&#1080;&#1103;<\/option><option value=\"&#1057;&#1083;&#1086;&#1074;&#1077;&#1085;&#1080;&#1103;\">&#1057;&#1083;&#1086;&#1074;&#1077;&#1085;&#1080;&#1103;<\/option><option value=\"&#1057;&#1086;&#1083;&#1086;&#1084;&#1086;&#1085;&#1086;&#1074;&#1099; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;\">&#1057;&#1086;&#1083;&#1086;&#1084;&#1086;&#1085;&#1086;&#1074;&#1099; &#1086;&#1089;&#1090;&#1088;&#1086;&#1074;&#1072;<\/option><option value=\"&#1057;&#1086;&#1084;&#1072;&#1083;&#1080;\">&#1057;&#1086;&#1084;&#1072;&#1083;&#1080;<\/option><option value=\"&#1070;&#1078;&#1085;&#1072;&#1103; &#1040;&#1092;&#1088;&#1080;&#1082;&#1072;\">&#1070;&#1078;&#1085;&#1072;&#1103; &#1040;&#1092;&#1088;&#1080;&#1082;&#1072;<\/option><option value=\"&#1048;&#1089;&#1087;&#1072;&#1085;&#1080;&#1103;\">&#1048;&#1089;&#1087;&#1072;&#1085;&#1080;&#1103;<\/option><option value=\"&#1064;&#1088;&#1080;-&#1051;&#1072;&#1085;&#1082;&#1072;\">&#1064;&#1088;&#1080;-&#1051;&#1072;&#1085;&#1082;&#1072;<\/option><option value=\"&#1057;&#1091;&#1076;&#1072;&#1085;\">&#1057;&#1091;&#1076;&#1072;&#1085;<\/option><option value=\"&#1057;&#1091;&#1076;&#1072;&#1085;, &#1070;&#1078;&#1085;&#1099;&#1081;\">&#1057;&#1091;&#1076;&#1072;&#1085;, &#1070;&#1078;&#1085;&#1099;&#1081;<\/option><option value=\"&#1057;&#1091;&#1088;&#1080;&#1085;&#1072;&#1084;\">&#1057;&#1091;&#1088;&#1080;&#1085;&#1072;&#1084;<\/option><option value=\"&#1064;&#1074;&#1077;&#1094;&#1080;&#1103;\">&#1064;&#1074;&#1077;&#1094;&#1080;&#1103;<\/option><option value=\"&#1064;&#1074;&#1077;&#1081;&#1094;&#1072;&#1088;&#1080;&#1103;\">&#1064;&#1074;&#1077;&#1081;&#1094;&#1072;&#1088;&#1080;&#1103;<\/option><option value=\"&#1057;&#1080;&#1088;&#1080;&#1103;\">&#1057;&#1080;&#1088;&#1080;&#1103;<\/option><option value=\"&#1058;&#1072;&#1081;&#1074;&#1072;&#1085;&#1100;\">&#1058;&#1072;&#1081;&#1074;&#1072;&#1085;&#1100;<\/option><option value=\"&#1058;&#1072;&#1076;&#1078;&#1080;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;\">&#1058;&#1072;&#1076;&#1078;&#1080;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1058;&#1072;&#1085;&#1079;&#1072;&#1085;&#1080;&#1103;\">&#1058;&#1072;&#1085;&#1079;&#1072;&#1085;&#1080;&#1103;<\/option><option value=\"&#1058;&#1072;&#1080;&#1083;&#1072;&#1085;&#1076;\">&#1058;&#1072;&#1080;&#1083;&#1072;&#1085;&#1076;<\/option><option value=\"&#1058;&#1086;&#1075;&#1086;\">&#1058;&#1086;&#1075;&#1086;<\/option><option value=\"&#1058;&#1086;&#1085;&#1075;&#1072;\">&#1058;&#1086;&#1085;&#1075;&#1072;<\/option><option value=\"&#1058;&#1088;&#1080;&#1085;&#1080;&#1076;&#1072;&#1076; &#1080; &#1058;&#1086;&#1073;&#1072;&#1075;&#1086;\">&#1058;&#1088;&#1080;&#1085;&#1080;&#1076;&#1072;&#1076; &#1080; &#1058;&#1086;&#1073;&#1072;&#1075;&#1086;<\/option><option value=\"&#1058;&#1091;&#1085;&#1080;&#1089;\">&#1058;&#1091;&#1085;&#1080;&#1089;<\/option><option value=\"&#1048;&#1085;&#1076;&#1077;&#1081;&#1082;&#1072;\">&#1048;&#1085;&#1076;&#1077;&#1081;&#1082;&#1072;<\/option><option value=\"&#1058;&#1091;&#1088;&#1082;&#1084;&#1077;&#1085;&#1080;&#1089;&#1090;&#1072;&#1085;\">&#1058;&#1091;&#1088;&#1082;&#1084;&#1077;&#1085;&#1080;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1058;&#1091;&#1074;&#1072;&#1083;&#1091;\">&#1058;&#1091;&#1074;&#1072;&#1083;&#1091;<\/option><option value=\"&#1059;&#1075;&#1072;&#1085;&#1076;&#1072;\">&#1059;&#1075;&#1072;&#1085;&#1076;&#1072;<\/option><option value=\"&#1059;&#1082;&#1088;&#1072;&#1080;&#1085;&#1072;\">&#1059;&#1082;&#1088;&#1072;&#1080;&#1085;&#1072;<\/option><option value=\"&#1054;&#1073;&#1098;&#1077;&#1076;&#1080;&#1085;&#1077;&#1085;&#1085;&#1099;&#1077; &#1040;&#1088;&#1072;&#1073;&#1089;&#1082;&#1080;&#1077; &#1069;&#1084;&#1080;&#1088;&#1072;&#1090;&#1099;\">&#1054;&#1073;&#1098;&#1077;&#1076;&#1080;&#1085;&#1077;&#1085;&#1085;&#1099;&#1077; &#1040;&#1088;&#1072;&#1073;&#1089;&#1082;&#1080;&#1077; &#1069;&#1084;&#1080;&#1088;&#1072;&#1090;&#1099;<\/option><option value=\"&#1042;&#1077;&#1083;&#1080;&#1082;&#1086;&#1073;&#1088;&#1080;&#1090;&#1072;&#1085;&#1080;&#1103;\">&#1042;&#1077;&#1083;&#1080;&#1082;&#1086;&#1073;&#1088;&#1080;&#1090;&#1072;&#1085;&#1080;&#1103;<\/option><option value=\"&#1057;&#1086;&#1077;&#1076;&#1080;&#1085;&#1077;&#1085;&#1085;&#1099;&#1077; &#1064;&#1090;&#1072;&#1090;&#1099;\">&#1057;&#1086;&#1077;&#1076;&#1080;&#1085;&#1077;&#1085;&#1085;&#1099;&#1077; &#1064;&#1090;&#1072;&#1090;&#1099;<\/option><option value=\"&#1059;&#1088;&#1091;&#1075;&#1074;&#1072;&#1081;\">&#1059;&#1088;&#1091;&#1075;&#1074;&#1072;&#1081;<\/option><option value=\"&#1059;&#1079;&#1073;&#1077;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;\">&#1059;&#1079;&#1073;&#1077;&#1082;&#1080;&#1089;&#1090;&#1072;&#1085;<\/option><option value=\"&#1042;&#1072;&#1085;&#1091;&#1072;&#1090;&#1091;\">&#1042;&#1072;&#1085;&#1091;&#1072;&#1090;&#1091;<\/option><option value=\"&#1042;&#1072;&#1090;&#1080;&#1082;&#1072;&#1085;\">&#1042;&#1072;&#1090;&#1080;&#1082;&#1072;&#1085;<\/option><option value=\"&#1042;&#1077;&#1085;&#1077;&#1089;&#1091;&#1101;&#1083;&#1072;\">&#1042;&#1077;&#1085;&#1077;&#1089;&#1091;&#1101;&#1083;&#1072;<\/option><option value=\"&#1042;&#1100;&#1077;&#1090;&#1085;&#1072;&#1084;\">&#1042;&#1100;&#1077;&#1090;&#1085;&#1072;&#1084;<\/option><option value=\"&#1049;&#1077;&#1084;&#1077;&#1085;\">&#1049;&#1077;&#1084;&#1077;&#1085;<\/option><option value=\"&#1047;&#1072;&#1084;&#1073;&#1080;&#1103;\">&#1047;&#1072;&#1084;&#1073;&#1080;&#1103;<\/option><option value=\"&#1047;&#1080;&#1084;&#1073;&#1072;&#1073;&#1074;&#1077;\">&#1047;&#1080;&#1084;&#1073;&#1072;&#1073;&#1074;&#1077;<\/option><\/select><\/div><\/div><!-- .wpforms-field-container --><div class=\"wpforms-submit-container\"><input type=\"hidden\" name=\"wpforms[id]\" value=\"2447\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages\/16065\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-2447\" class=\"wpforms-submit\" data-alt-text=\"&#1055;&#1086;&#1089;&#1099;&#1083;&#1072;&#1102;...\" data-submit-text=\"&#1054;&#1090;&#1087;&#1088;&#1072;&#1074;&#1080;&#1090;&#1100;\" aria-live=\"assertive\" value=\"wpforms-submit\">&#1054;&#1090;&#1087;&#1088;&#1072;&#1074;&#1080;&#1090;&#1100;<\/button><img decoding=\"async\" src=\"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/wpforms\/assets\/images\/submit-spin.svg\" class=\"wpforms-submit-spinner\" style=\"display: none;\" width=\"26\" height=\"26\" alt=\"&#1047;&#1072;&#1075;&#1088;&#1091;&#1079;&#1082;&#1072;\" title=\"\"><\/div><\/form><\/div>  <!-- .wpforms-container --><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-138d73f0 e-flex e-con-boxed e-con e-parent\" data-id=\"138d73f0\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7f19437 elementor-widget elementor-widget-heading\" data-id=\"7f19437\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1054;&#1073;&#1088;&#1072;&#1079;&#1086;&#1074;&#1072;&#1085;&#1080;&#1077;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a83b8ed elementor-widget elementor-widget-text-editor\" data-id=\"a83b8ed\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>1994 - 1999 &#1057;&#1087;&#1077;&#1094;&#1080;&#1072;&#1083;&#1080;&#1079;&#1072;&#1094;&#1080;&#1103; &#1087;&#1086; &#1084;&#1077;&#1076;&#1080;&#1094;&#1080;&#1085;&#1077;\n&#1059;&#1085;&#1080;&#1074;&#1077;&#1088;&#1089;&#1080;&#1090;&#1077;&#1090; &#1044;&#1086;&#1082;&#1091;&#1079; &#1069;&#1081;&#1083;&#1091;&#1083;, &#1084;&#1077;&#1076;&#1080;&#1094;&#1080;&#1085;&#1089;&#1082;&#1080;&#1081; &#1092;&#1072;&#1082;&#1091;&#1083;&#1100;&#1090;&#1077;&#1090;, &#1058;&#1091;&#1088;&#1094;&#1080;&#1103;\n\n<\/li><li>1986 - 1992 &#1057;&#1090;&#1077;&#1087;&#1077;&#1085;&#1100; &#1073;&#1072;&#1082;&#1072;&#1083;&#1072;&#1074;&#1088;&#1072;\n&#1059;&#1085;&#1080;&#1074;&#1077;&#1088;&#1089;&#1080;&#1090;&#1077;&#1090; &#1044;&#1086;&#1082;&#1091;&#1079; &#1069;&#1081;&#1083;&#1091;&#1083;, &#1084;&#1077;&#1076;&#1080;&#1094;&#1080;&#1085;&#1089;&#1082;&#1080;&#1081; &#1092;&#1072;&#1082;&#1091;&#1083;&#1100;&#1090;&#1077;&#1090;, &#1058;&#1091;&#1088;&#1094;&#1080;&#1103;\t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ea8358b elementor-widget elementor-widget-heading\" data-id=\"ea8358b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1044;&#1077;&#1103;&#1090;&#1077;&#1083;&#1100;&#1085;&#1086;&#1089;&#1090;&#1100; &#1074; &#1085;&#1072;&#1091;&#1095;&#1085;&#1099;&#1093; &#1078;&#1091;&#1088;&#1085;&#1072;&#1083;&#1072;&#1093;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bc0544f elementor-widget elementor-widget-text-editor\" data-id=\"bc0544f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>2021 - &#1058;&#1077;&#1082;&#1091;&#1097;&#1080;&#1081; &#1078;&#1091;&#1088;&#1085;&#1072;&#1083; &#1080;&#1089;&#1089;&#1083;&#1077;&#1076;&#1086;&#1074;&#1072;&#1085;&#1080;&#1081; &#1088;&#1072;&#1089;&#1089;&#1077;&#1103;&#1085;&#1085;&#1086;&#1075;&#1086; &#1089;&#1082;&#1083;&#1077;&#1088;&#1086;&#1079;&#1072;\n&#1043;&#1083;&#1072;&#1074;&#1085;&#1099;&#1081; &#1088;&#1077;&#1076;&#1072;&#1082;&#1090;&#1086;&#1088;\t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6775816 elementor-widget elementor-widget-heading\" data-id=\"6775816\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1063;&#1083;&#1077;&#1085;&#1089;&#1090;&#1074;&#1086; \/ &#1076;&#1086;&#1083;&#1078;&#1085;&#1086;&#1089;&#1090;&#1080; &#1074; &#1085;&#1072;&#1091;&#1095;&#1085;&#1099;&#1093; &#1086;&#1088;&#1075;&#1072;&#1085;&#1080;&#1079;&#1072;&#1094;&#1080;&#1103;&#1093;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0a3c38 elementor-widget elementor-widget-text-editor\" data-id=\"d0a3c38\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>1999 - &#1055;&#1086;&#1089;&#1090;&#1086;&#1103;&#1085;&#1085;&#1086; &#1076;&#1077;&#1081;&#1089;&#1090;&#1074;&#1091;&#1102;&#1097;&#1072;&#1103; &#1058;&#1091;&#1088;&#1077;&#1094;&#1082;&#1072;&#1103; &#1085;&#1077;&#1074;&#1088;&#1086;&#1083;&#1086;&#1075;&#1080;&#1095;&#1077;&#1089;&#1082;&#1072;&#1103; &#1072;&#1089;&#1089;&#1086;&#1094;&#1080;&#1072;&#1094;&#1080;&#1103;\n&#1063;&#1083;&#1077;&#1085;\t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9cb9ae8 elementor-widget elementor-widget-heading\" data-id=\"9cb9ae8\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1052;&#1077;&#1088;&#1086;&#1087;&#1088;&#1080;&#1103;&#1090;&#1080;&#1103; &#1087;&#1086; &#1091;&#1095;&#1072;&#1089;&#1090;&#1080;&#1102; &#1074; &#1082;&#1086;&#1085;&#1075;&#1088;&#1077;&#1089;&#1089;&#1072;&#1093; &#1080; &#1089;&#1080;&#1084;&#1087;&#1086;&#1079;&#1080;&#1091;&#1084;&#1072;&#1093;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6d86502 elementor-widget elementor-widget-text-editor\" data-id=\"6d86502\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>12 &#1085;&#1086;&#1103;&#1073;&#1088;&#1103; 2022 - 13 &#1085;&#1086;&#1103;&#1073;&#1088;&#1103; 2022 7-&#1081; &#1089;&#1080;&#1084;&#1087;&#1086;&#1079;&#1080;&#1091;&#1084; &#1087;&#1086; &#1082;&#1086;&#1075;&#1085;&#1080;&#1090;&#1080;&#1074;&#1085;&#1099;&#1084; &#1088;&#1072;&#1089;&#1089;&#1090;&#1088;&#1086;&#1081;&#1089;&#1090;&#1074;&#1072;&#1084; &#1087;&#1088;&#1080; &#1088;&#1072;&#1089;&#1089;&#1077;&#1103;&#1085;&#1085;&#1086;&#1084; &#1089;&#1082;&#1083;&#1077;&#1088;&#1086;&#1079;&#1077;<br>&#1052;&#1086;&#1076;&#1077;&#1088;&#1072;&#1090;&#1086;&#1088;<p>&#1048;&#1079;&#1084;&#1080;&#1088;, &#1058;&#1091;&#1088;&#1094;&#1080;&#1103;<\/p><\/li><li>26 &#1086;&#1082;&#1090;&#1103;&#1073;&#1088;&#1103; 2022 - 28 &#1086;&#1082;&#1090;&#1103;&#1073;&#1088;&#1103; 2022 ECTRIMS 2022<br>&#1059;&#1095;&#1072;&#1089;&#1090;&#1085;&#1080;&#1082;<p>&#1040;&#1084;&#1089;&#1090;&#1077;&#1088;&#1076;&#1072;&#1084;, &#1053;&#1080;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&#1099;<\/p><\/li><li>25 &#1080;&#1102;&#1085;&#1103; 2022 - 28 &#1080;&#1102;&#1085;&#1103; 2022 &#1050;&#1086;&#1085;&#1075;&#1088;&#1077;&#1089;&#1089; EAN<br>&#1059;&#1095;&#1072;&#1089;&#1090;&#1085;&#1080;&#1082;<p>&#1042;&#1077;&#1085;&#1072;, &#1040;&#1074;&#1089;&#1090;&#1088;&#1080;&#1103;<\/p><\/li><li>18 &#1084;&#1072;&#1103; 2022 - 19 &#1084;&#1072;&#1103; 2022 IMSCOGS 2022<br>&#1059;&#1095;&#1072;&#1089;&#1090;&#1085;&#1080;&#1082;<p>&#1041;&#1086;&#1088;&#1076;&#1086;, &#1060;&#1088;&#1072;&#1085;&#1094;&#1080;&#1103;<\/p><\/li><li>02 &#1072;&#1087;&#1088;&#1077;&#1083;&#1103; 2022 - 07 &#1072;&#1087;&#1088;&#1077;&#1083;&#1103; 2022 AAN 2022<br>&#1059;&#1095;&#1072;&#1089;&#1090;&#1085;&#1080;&#1082;<p>&#1042;&#1072;&#1096;&#1080;&#1085;&#1075;&#1090;&#1086;&#1085;, &#1057;&#1086;&#1077;&#1076;&#1080;&#1085;&#1077;&#1085;&#1085;&#1099;&#1077; &#1064;&#1090;&#1072;&#1090;&#1099; &#1040;&#1084;&#1077;&#1088;&#1080;&#1082;&#1080;<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-034f82f elementor-widget elementor-widget-heading\" data-id=\"034f82f\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1048;&#1089;&#1089;&#1083;&#1077;&#1076;&#1086;&#1074;&#1072;&#1085;&#1080;&#1103;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a06971 elementor-widget elementor-widget-text-editor\" data-id=\"2a06971\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t&lt;ul&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)&lt;\/strong&gt;\n    &lt;br&gt;Authors: &#350;en S., K&Uuml;RT&Uuml;NC&Uuml; M., Demir S., G&Uuml;ND&Uuml;Z T., Demirel E., T&uuml;t&uuml;nc&uuml; M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of the synchronized telerehabilitation-based upper extremity training program on hand-arm functions in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Dastan S., ERTEK&#304;N &Ouml;., &Ouml;zdo&#287;ar A. T., Kahraman T., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of Telerehabilitation-Based Motor Imagery Training on Pain and Related Factors in People With Multiple Sclerosis: Randomized Controlled Pilot Trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Karakas H., Kahraman T., &Ouml;zdo&#287;ar A. T., Baba C., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Toscano S., Spelman T., Ozakbas S., Alroughani R., Chisari C. G., Lo Fermo S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prevalence and Magnitude of Perceived Dual-Task Difficulties in People With Multiple Sclerosis: An International Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abas&#305;yan&#305;k Z., Pedull&agrave; L., Kahraman T., Soler B., Santoyo-Medina C., Tacchino A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The relationship between work difficulties and physical disability, cognitive and social cognitive impairment and subcortical gray matter atrophy in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Aslan T., &Ouml;zdo&#287;ar A. T., Sagici O., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Sharmin S., Malpas C., &Ouml;ZAKBA&#350; S., Lechner-Scott J., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Investigation of the Relationship Between Coping With the Disease and Afecting Cognitive, Physical, and Psychosocial Factors in People with Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sagici O., &Ouml;ZDO&#286;AR A. T., Aslan T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ccedil;EL&#304;K M., Baba C., IRMAK &Ccedil;., &Ouml;zbakba&#351; S., AVKAN O&#286;UZ V.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Signori A., Ponzano M., Kalincik T., &Ouml;ZAKBA&#350; S., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Predictors of relapse severity in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Abasiyanik Z., Simsek Y., Ozdogar A. T., Sagici O., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cognition as a parameter in monitoring the effect of multiple sclerosis relapse treatment: A prospective controlled study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Piri Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Yavas I., SAMADZADE U., &Ouml;ZDO&#286;AR A. T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Baba C., Yavas I., SAMADZADE U., &Ouml;ZDO&#286;AR A. T.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Levitz D., Chao Foong Y., Sanfilippo P., Spelman T., Rath L., Roldan A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Investigating the relationship of theory of mind and empathy with neuroimaging, neuropsychological, and neuropsychiatric data in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Aslan T., &Ouml;ZDO&#286;AR A. T., Sagici O., Yigit P., Zorlu N., BORA &#304;. E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies&lt;\/strong&gt;\n    &lt;br&gt;Authors: Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Risk of secondary progressive multiple sclerosis after early worsening of disability&lt;\/strong&gt;\n    &lt;br&gt;Authors: Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Dual-task difficulties as a risk factor for unemployment in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., Temiz H., Abasiyanik Z., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The risk of secondary progressive multiple sclerosis is geographically determined but modifiable&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Roos I., Simpson-Yap S., Malpas C., S&aacute;nchez M. M., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Tuncer A., Terzi M., B&Uuml;N&Uuml;L S. D., Ozen-Acar P., Altunrende B., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Feasibility of Telerehabilitation-Based Pelvic Floor Muscle Training for Urinary Incontinence in People With Multiple Sclerosis: A Randomized, Controlled, Assessor-Blinded Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yavas I., Kahraman T., Sagici O., Ozdogar A. T., Yigit P., Baba C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability accrual in primary and secondary progressive multiple sclerosis.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Hughes S., McDonnell G., Malpas C. B., Sharmin S., BOZ C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., &Ouml;ZAKBA&#350; S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhu C., Kalincik T., Horakova D., Zhou Z., Buzzard K., Skibina O., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity&mdash;Does it matter?&lt;\/strong&gt;\n    &lt;br&gt;Authors: T&uuml;t&uuml;nc&uuml; M., Demir S., Arslan G., Din&ccedil; &Ouml;., &#350;en S., G&Uuml;ND&Uuml;Z T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Daruwalla C., Shaygannejad V., &Ouml;ZAKBA&#350; S., Havrdova E. K., Horakova D., Alroughani R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: BOZ C., &Ouml;ZAKBA&#350; S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Narrative review based on fingolimod therapy in pediatric MS.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Piri Cinar B., Konuskan B., Anlar B., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects of prolonged walking on dual-task walking performance in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Veldkamp R., ERTEK&#304;N &Ouml;., Kalron A., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Psychometric properties of three self-report questionnaires assessing dual-task difficulties in people with multiple sclerosis: A multicenter study within the RIMS network&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Pedulla L., Kahraman T., D&rsquo;Hooge M., Santoyo-Medina C., Soler B., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association between work-related difficulties and dual-task ability in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Temiz H., Kahraman T., Abasiyanik Z., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness in multiple sclerosis: A methodological comparison&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., &Ouml;ZAKBA&#350; S., Alroughani R., TERZ&#304; M., Hodgkinson S., Laureys G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Ertekin &Ouml;., Kahraman T., Dastan S., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., Horakova D., &Ouml;ZAKBA&#350; S., Alroughani R., Onofrj M., Kalincik T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network&lt;\/strong&gt;\n    &lt;br&gt;Authors: Signori A., Lorscheider J., Vukusic S., Trojano M., Iaffaldano P., Hillert J., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Preference-Based Multiple Sclerosis Index: an assessment of its psychometric properties and translation into Turkish&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., Ozdogar A. T., Abasiyanik Z., Sagici O., Baba C., Ertekin &Ouml;., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COV&#304;D-19 in Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: &#350;en S., Arslan G., T&uuml;t&uuml;nc&uuml; M., Demir S., Din&ccedil; &Ouml;., G&Uuml;ND&Uuml;Z T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Ozcelik S., Kaya E., Samedzada U., Ozdogar A. T., Cevik S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Ozdogar A. T., &Ouml;Z&Ccedil;EL&#304;K S., KAYA E., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Factors related to restless leg syndrome in neuromyelitis optica spectrum disorder&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., KAYA E., Sagici O., Dastan S., Karakas H., Baba C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Predictive ability of the original and short form of the activities-specific balance confidence scale and its individual items for falls in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Baba C., Sagici O., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Olmez O., Baba C., Abasiyanik Z., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Confirmed disability progression as a marker of permanent disability in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects and safety of exergaming in persons with multiple sclerosis during corticosteroid treatment: a pilot study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Baba C., Kahraman T., Sagici O., Dastan S., Ertekin &Ouml;., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Kaya E., Ozdogar A.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness and Persistence of Cladribine Tablets from GLIMPSE: Results from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Sustained attention during prolonged walking in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Veldkamp R., Ertekin &Ouml;., Kalron A., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar T., Sagici O., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., &Ccedil;&#304;NAR B. P., Baba C., Kosehasanogullari G.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Restless legs syndrome and related factors in people with multiple sclerosis in Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;zdo&#287;ar A. T., Ertekin &Ouml;., Kahraman T., Baba C., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Tuncer A., &Ouml;ZAKBA&#350; S., Uzunkopru C., Baba C., Demir S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;zakba&#351; S., Baba C., Do&#287;an Y., Cevik S., &Ouml;z&ccedil;elik S., Kaya E.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Fatigue is associated with physical inactivity in people with multiple sclerosis despite different environmental backgrounds: Merging and comparing cohorts from Turkey and Israel&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZDO&#286;AR A. T., Kahraman T., &Ouml;ZAKBA&#350; S., Achiron A., Kalron A.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Yigit P., Dastan S., Hancer P., Sagici O., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., De Brouwer E., Kalincik T., Rijke N., Hillert J. A., Walton C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018&lt;\/strong&gt;\n    &lt;br&gt;Authors: Moradi N., Sharmin S., Malpas C., &Ouml;ZAKBA&#350; S., Shaygannejad V., TERZ&#304; M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of exergaming in persons with multiple sclerosis with restless legs syndrome: a randomized controlled trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Ertekin O., Kahraman T., Aslan A. T., Dastan S., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparatve effectveness of beta-nterferons and glatramer acetate on physcal and cogntve functons: 6-month follow-up study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Aslan T., Abasiyanik Z., Ozdogar A. T.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Malpas C., Roos I., Diouf I., Alroughani R., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yigit P., Sagici O., Abasiyanik Z., Baba C., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;External validation of the MSBase model of individual treatment response (Crystal Ball 1.0)&lt;\/strong&gt;\n    &lt;br&gt;Authors: Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Terzi M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Boz C., Buzzard K., Skibina O., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Incidence and predisposing factors of COVID-19 in patients living with multiple sclerosis: Results from a prospective multiple sclerosis cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Berktas M., Aslan T., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar A. T., Sagici O., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Sharmin S., Ozakbas S., Horakova D., Havrdova E. K., Boz C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relapse during the washout period predicts time to relapse after switching to cladribine&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhong M., van der Walt A., Hodgkinson S., Izquierdo G., Eichau S., Kalincik T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cognition as a parameter that should not be ignored when evaluating the effect of relapse treatment: A prospective controlled study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-world experience with cladribine in the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Hodgkinson S., Madueno S. E., Izquierdo G., Buzzard K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozdogar A. T., Baba C., Ozcelik S., Kaya E.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., &Ouml;ZDO&#286;AR A. T., Abasiyanik Z., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Determinants of therapeutic lag in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Does the reason for the switch to fingolimod affect the treatment response?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Aslan T., Ozdogar A. T., Abasiyanik Z., Sagici O.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;A comparative study of the effects of yoga and clinical Pilates training on walking, cognition, respiratory functions, and quality of life in persons with multiple sclerosis: A quasi-experimental study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abas&#305;yan&#305;k Z., Yi&#287;it P., &Ouml;ZDO&#286;AR A. T., Kahraman T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Five-year real-world data on fingolimod treatment&rsquo;s effects on cognitive function&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., Piri Cinar B., Yigit P., Baba C., Sagici O.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression&lt;\/strong&gt;\n    &lt;br&gt;Authors: De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The effectiveness of natalizumab vs fingolimod&ndash;A comparison of international registry studies&lt;\/strong&gt;\n    &lt;br&gt;Authors: Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., S&oslash;rensen P. S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yigit P., A&ccedil;&#305;kg&ouml;z A., Mehdiyev Z., Day&#305; A., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Karabudak R., Schiavetti I., Demir S., Ozakbas S., Tutuncu M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: Uzunkopru C., Tutuncu M., Gunduz T., G&Uuml;M&Uuml;&#350; H., Sen S., Demir S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: ERTEK&#304;N &Ouml;., Kahraman T., Aras M., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Validity and reliability of \"Cognitive Reserve Index Questionnaire\" for the Turkish Population&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., Yigit P., Akyuz Z., Sagici O., Abasiyanik Z., &Ouml;ZDO&#286;AR A. T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;High and low efficacy therapy in secondary progressive multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., &Ouml;ZDO&#286;AR A. T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability Accrual in Primary Progressive &amp; Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Harding-Forrester S., Roos I., Sharmin S., Diouf I., Malpas C., Nguyen A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Ertekin &Ouml;., Baba C., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Delay from treatment start to full effect of immunotherapies for multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Frascoli F., Casey R., William Brown J., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Minh Le M. L., Malpas C., Sharmin S., H\n    &lt;br&gt;Citations: Unknown, Year: Unknown\n  &lt;\/li&gt;\n&lt;li&gt;\n        &lt;strong&gt;Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study&lt;\/strong&gt;&lt;br&gt;\n        Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.&lt;br&gt;\n        Year: 2021 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a&lt;\/strong&gt;&lt;br&gt;\n        Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.&lt;br&gt;\n        Year: 2021 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Balance and Gait Impairment in Persons with Multiple Sclerosis with the Absence of Clinical Disability&lt;\/strong&gt;&lt;br&gt;\n        Ayan H., ERTEK&#304;N &Ouml;., Kahraman T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Delay from treatment start to full effect of immunotherapies for multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Explanatory factors of balance confidence in persons with multiple sclerosis: Beyond the physical functions&lt;\/strong&gt;&lt;br&gt;\n        Abasiyanik Z., &Ouml;zdo&#287;ar A. T., Sagici O., Kahraman T., Baba C., Ertekin &Ouml;., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., Kahraman T., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early clinical markers of aggressive multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder&lt;\/strong&gt;&lt;br&gt;\n        Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZ&#304; M., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The effects of Clinical Pilates training on walking, balance, fall risk, respiratory, and cognitive functions in persons with multiple sclerosis: A randomized controlled trial&lt;\/strong&gt;&lt;br&gt;\n        Abasiyanik Z., ERTEK&#304;N &Ouml;., Kahraman T., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Risk of secondary progressive multiple sclerosis: A longitudinal study&lt;\/strong&gt;&lt;br&gt;\n        Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Determinant Role of Magnetic Resonance Imaging in Transition of Clinical Isolated Syndrome to Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        P&#304;R&#304; &Ccedil;&#304;NAR B., &Ouml;Z D., B&#304;RCAN KUR&#350;UN B., G&Uuml;RKAN M., &Ouml;ZT&Uuml;RK O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Determinant Role of Magnetic Resonance Imaging in Conversion from Clinically Isolated Syndrome to Multiple Sclerosis (Klinik &#304;zole Sendromda Multipl Skleroza D&ouml;n&uuml;&#351;&uuml;mde Manyetik Rezonans G&ouml;r&uuml;nt&uuml;lemenin Belirleyici Rol&uuml;)&lt;\/strong&gt;&lt;br&gt;\n        P&#304;R&#304; &Ccedil;&#304;NAR B., &Ouml;Z D., B&#304;RCAN KUR&#350;UN B., G&Uuml;RKAN M. A., &Ouml;ZT&Uuml;RK O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        BOZ C., TERZ&#304; M., Ozer B., Turkoglu R., KARABUDAK R., EFEND&#304; H., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of hormonal changes on the neurological status in the menstrual cycle of patient with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Yorgun Y. G., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., Honan C. A., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The 20-year history: Change of multiple sclerosis patient profile over 20 years&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., &Ccedil;&#304;NAR B. P., Kahraman T.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Oz D., Kosehasanogullari G., Kursun B. B., Kahraman T.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Frequency, type, distribution of pain and related factors in persons with multiple sclerosis'&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive involvement in clinically isolated syndrome and relationship with fatigue&lt;\/strong&gt;&lt;br&gt;\n        &Ccedil;&#304;NAR B. P., Yigit P., Gurkan M. A., Ozturk O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effects of cigarette smoking on respiratory problems and functional levels in multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Aktan R., &Ouml;ZALEVL&#304; S., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Relationship between Trunk Flexor Muscle Strength and Walking, Balance, and Falls in Multiple Sclerosis Patients (Multipl skleroz hastalar&#305;nda g&ouml;vde fleks&ouml;r kas kuvvetinin y&uuml;r&uuml;me,denge ve d&uuml;&#351;me ile ili&#351;kis)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Balance and Gait Disorder in Early Stages of Multiple Sclerosis (Multipl sklerozun erken evrelerinde denge ve y&uuml;r&uuml;y&uuml;&#351; bozuklu&#287;u)&lt;\/strong&gt;&lt;br&gt;\n        AYAN H., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Frequency, Type, Distribution of Pain and Related Factors in Individuals with Multiple Sclerosis (Multipl sklerozlu bireylerde a&#287;r&#305;n&#305;n s&#305;kl&#305;&#287;&#305;, tipi, da&#287;&#305;l&#305;m&#305; ve a&#287;r&#305;yla ili&#351;kili etmenler)&lt;\/strong&gt;&lt;br&gt;\n        KAHRAMAN T., &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Relationship between Respiratory Muscle Strength and Cognitive Functions in Multiple Sclerosis (Multipl sklerozda solunum kas kuvveti ile kognitif fonksiyonlararas&#305;nda ili&#351;ki)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., Y&#304;&#286;&#304;T P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effect of Clinical Pilates Training on Balance, Walking, Fall Risk, Respiratory Functions, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalar&#305;nda klinik Pilates e&#287;itiminin denge, y&uuml;r&uuml;me,d&uuml;&#351;me riski, solunum fonksiyonlar&#305; ve kognitif fonksiyonlar &uuml;zerineetkisi: randomize kontroll&uuml; &ccedil;al&#305;&#351;ma)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Turkoglu R., Tamam Y., TERZ&#304; M., Taskapilioglu O., Y&Uuml;CESAN C., et al.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Smoking is associated with walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozdogar A., Kahraman T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Long-term test-retest reliability and validity of the Six Spot Step Test in individuals with multiple sclerosis (Alt&#305; Nokta Ad&#305;m Testi&rsquo;nin multiple sklerozlu bireylerdeki uzun d&ouml;nem test-tekrar test uyum ve g&uuml;venirlili&#287;i)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;FEASIBILITY OF A 6-MONTH YOGA PROGRAM TO IMPROVE THE PHYSICAL AND PSYCHOSOCIAL STATUS OF PERSONS WITH MULTIPLE SCLEROSIS AND THEIR FAMILY MEMBERS&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., Yigit P., Hosgel I., Mehdiyev Z., ERTEK&#304;N &Ouml;., et al.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Upper Extremity Dysfunction in Multiple Sclerosis Patients without Clinical Disability (Klinik &ouml;z&uuml;r&uuml; olmayan Multipl skleroz hastalar&#305;nda &uuml;st ekstremite fonksiyon bozuklu&#287;u)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Restless Legs Syndrome and Related Factors in Multiple Sclerosis Patients (Multipl sklerozlu hastalar&#305;nda huzursuz bacak sendromu ve ili&#351;kili fakt&ouml;rler)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., Y&#304;&#286;&#304;T P., HO&#350;GEL &#304;., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effect of Video Game Based Physical Activity Approach on Upper Extremity Function, Walking, Balance, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalar&#305;nda video oyunlari temelli fiziksel aktivite yakla&#351;&#305;m&#305;n&#305;n &uuml;st ekstremite fonksiyonu, y&uuml;r&uuml;me, denge ve kognitif fonksiyonlar &uuml;zerine etkisi: randomize kontroll&uuml; &ccedil;al&#305;&#351;ma)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., KAHRAMAN T., Y&#304;&#286;&#304;T P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Yigit P., Cinar B. P., Limoncu H., Kahraman T., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., KAYA &Ouml;Z&Ccedil;EL&#304;K P., Baser H., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;\"No evidence of disease activity - cognition\" in relapsing-remitting multiple sclerosis: recommendation for an extensive assessment of disease activity&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Yigit P., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: SCI-Expanded\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., Kosehasanogullari G., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Social Cognition in Multiple Sclerosis: a Meta-Analysis&lt;\/strong&gt;&lt;br&gt;\n        BORA &#304;. E., &Ouml;ZAKBA&#350; S., Velakoulis D., Walterfang M.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., SAVCI S., Poyraz E. C., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Paced auditory serial addition test: National normative data&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Gurkan M. A., Ozturk O., Oz D., Kursun B. B.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Reassessment of Lhermitte&rsquo;s sign in multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        BECKMANN Y., &Ouml;ZAKBA&#350; S., Bulbul N. G., Kosehasanogullari G., SE&Ccedil;&#304;L Y., Bulut O., et al.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive Impairment in Multiple Sclerosis: Historical Aspects, Current Status, and Beyond&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Determinants of physical activity in minimally impaired people with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., SAVCI S., Coskuner-Poyraz E., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too&lt;\/strong&gt;&lt;br&gt;\n        Kosehasanogullari G., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Uveitis associated with multiple sclerosis: complications and visual prognosis&lt;\/strong&gt;&lt;br&gt;\n        Kaya D., KAYA M., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Contingent Negative Variation Is Associated with Cognitive Dysfunction and Secondary Progressive Disease Course in Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        UYSAL U., Idiman F., Idiman E., &Ouml;ZAKBA&#350; S., Karakas S., Bruce J.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early Deterioration In Quality Of Life And Physical Functioning Of Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S., &#304;D&#304;MAN E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis.&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: Comparison of the results with that of multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Importance of neutralizing antibody positivity in Turkish multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        KAYA D., TUFAN S., &Ouml;ZAKBA&#350; S., BAHAR H., ADA E., &#304;D&#304;MAN E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Sexual dysfunction in multiple sclerosis: Gender differences&lt;\/strong&gt;&lt;br&gt;\n        Celik D. B., Poyraz E. C., Bingol A., Idiman E., &Ouml;ZAKBA&#350; S., Kaya D.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Comparison of Physical Activity Status, Exercise Perception and Quality of Life Between Clinically Isolated Syndrome and Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Cinar B. P., ALGUN Z. C., Idiman E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effects of Low and Severe Disability on Walking Abilities and Quality of Life in Multiple Sclerosis Patients: 6-Month Follow-up Study&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E., ALGUN Z. C.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., KAYA D., Idiman E.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Inflammatory demyelinating central nervous system diseases in childhood: Clinical and paraclinical profiles in 133 patients&lt;\/strong&gt;&lt;br&gt;\n        Kaya D., Idiman E., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Quality of Life, Fatigue and Balance Improvements after Home-Based Exercise Program in Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E., ALGUN Z. C.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Symptomatic Menagement in Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of cognitive function and physical activity on the ability to learn and reproduce physiotherapy exercises in healthy subjects&lt;\/strong&gt;&lt;br&gt;\n        Kara B., GEN&Ccedil; A., Colakoglu B. D., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: SCI-Expanded\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;A Case of Fever of Unknown Origin: Co-existence of Kikuchi-Fujimoto Disease and Acute Disseminated Encephalomyelitis (ADEM)&lt;\/strong&gt;&lt;br&gt;\n        AVKAN O&#286;UZ V., Yapar N., &Ouml;ZAKBA&#350; S., Demir-Onder K., Aktas E., ALP &Ccedil;AVU&#350; S., et al.&lt;br&gt;\n        Year: 2010 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., &Ouml;zakba&#351; S., Do&#287;an Y., Kosehasanogullari G.&lt;br&gt;\n        Year: 2009 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Akdede B. B., Kosehasanogullari G., Aksan O., Idiman E.&lt;br&gt;\n        Year: 2007 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Idiman E., Yulug B., Pakoz B., Bahar H., Gulay Z.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in Multiple Sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Yozbatiran N., Baskurt F., Baskurt Z., Ozakbas S., Idiman E.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., Uzunel F., Ozakbas S., Yozbatiran N., Oguz M., Callioglu B., et al.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Ormeci B., Idiman E.&lt;br&gt;\n        Year: 2005 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Intrathecal sICAM-1 production in multiple sclerosis - Correlation with triple dose Gd-DTPA MRI enhancement and IgG index&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Idiman F., Kirkali G., Ozakbas S., Oktay G., Cakmakci H., et al.&lt;br&gt;\n        Year: 2005 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Ozakbas S., Cakmakci H., Idiman F., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features&lt;\/strong&gt;&lt;br&gt;\n        Donmez B., Ozakbas S., Oktem M., Gedizlioglu M., Coker I., Genc A. A., et al.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Cagiran I., Ormeci B., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Ormeci B., Akdede B. B., ALPTEK&#304;N K., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Idiman E., Baklan B., Yulug B.&lt;br&gt;\n        Year: 2003 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Nitric oxide as an activity marker in multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., Ozakbas S.&lt;br&gt;\n        Year: 2003 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n&lt;\/ul&gt;\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u041f\u0440\u043e\u0444\u0435\u0441\u0441\u043e\u0440 \u0421\u0435\u0440\u043a\u0430\u043d \u041e\u0437\u0430\u043a\u0431\u0430\u0448, \u0434\u043e\u043a\u0442\u043e\u0440 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u043d\u0430\u0443\u043a<\/p>\n","protected":false},"author":3,"featured_media":16068,"parent":14364,"menu_order":51,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[273],"tags":[166],"class_list":["post-16065","page","type-page","status-publish","has-post-thumbnail","hentry","category-273","tag--medicalpoint-izmir","bf-cat-273","bf-cat-543"],"rankMath":{"parentDomain":"medicalpointinternational.com","noFollowDomains":[],"noFollowExcludeDomains":[],"noFollowExternalLinks":false,"featuredImageNotice":"\u041f\u043e\u043a\u0430\u0437\u0430\u043d\u043d\u043e\u0435 \u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435 \u0434\u043e\u043b\u0436\u043d\u043e \u0431\u044b\u0442\u044c \u0440\u0430\u0437\u043c\u0435\u0440\u043e\u043c \u043d\u0435 \u043c\u0435\u043d\u0435\u0435 200 \u043d\u0430 200 \u043f\u0438\u043a\u0441\u0435\u043b\u0435\u0439, \u0447\u0442\u043e\u0431\u044b \u0435\u0433\u043e \u043c\u043e\u0433\u043b\u0438 \u0443\u0432\u0438\u0434\u0435\u0442\u044c Facebook \u0438 \u0434\u0440\u0443\u0433\u0438\u0435 \u0441\u0430\u0439\u0442\u044b \u0441\u043e\u0446\u0438\u0430\u043b\u044c\u043d\u044b\u0445 \u0441\u0435\u0442\u0435\u0439.","pluginReviewed":false,"postSettings":{"linkSuggestions":true,"useFocusKeyword":false},"frontEndScore":false,"postName":"%d0%bf%d1%80%d0%be%d1%84%d0%b5%d1%81%d1%81%d0%be%d1%80-%d1%81%d0%b5%d1%80%d0%ba%d0%b0%d0%bd-%d0%be%d0%b7%d0%b0%d0%ba%d0%b1%d0%b0%d1%88","permalinkFormat":"https:\/\/medicalpointinternational.com\/ru\/%pagename%\/","showLockModifiedDate":true,"assessor":{"focusKeywordLink":"https:\/\/medicalpointinternational.com\/wp-admin\/edit.php?focus_keyword=%focus_keyword%&post_type=%post_type%","hasTOCPlugin":true,"primaryTaxonomy":false,"serpData":{"title":"","description":"","focusKeywords":"","pillarContent":false,"canonicalUrl":"","breadcrumbTitle":"","advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":"","facebookHasOverlay":false,"facebookImageOverlay":"","facebookAuthor":"","twitterCardType":"","twitterUseFacebook":true,"twitterTitle":"","twitterDescription":"","twitterImage":"","twitterImageID":"","twitterHasOverlay":false,"twitterImageOverlay":"","twitterPlayerUrl":"","twitterPlayerSize":"","twitterPlayerStream":"","twitterPlayerStreamCtype":"","twitterAppDescription":"","twitterAppIphoneName":"","twitterAppIphoneID":"","twitterAppIphoneUrl":"","twitterAppIpadName":"","twitterAppIpadID":"","twitterAppIpadUrl":"","twitterAppGoogleplayName":"","twitterAppGoogleplayID":"","twitterAppGoogleplayUrl":"","twitterAppCountry":"","robots":{"index":true},"twitterAuthor":"\u0438\u043c\u044f \u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u0442\u0435\u043b\u044f","primaryTerm":0,"authorName":"Ali \u00d6zgen\u00e7","titleTemplate":"%title% %sep% %sitename%","descriptionTemplate":"%excerpt%","showScoreFrontend":true,"lockModifiedDate":false},"powerWords":[],"diacritics":{"A":"[\\u0410\\u0430]","B":"[\\u0411\\u0431]","V":"[\\u0412\\u0432]","G":"[\\u0413\\u0433]","D":"[\\u0414\\u0434]","YE":"[\\u0415\\u0435]","YO":"[\\u0401\\u0451]","ZH":"[\\u0416\\u0436]","Z":"[\\u0417\\u0437]","EE":"[\\u0418\\u0438]","YI":"[\\u0419\\u0439]","K":"[\\u041A\\u043A]","L":"[\\u041B\\u043B]","M":"[\\u041C\\u043c]","P":"[\\u041F\\u043F]","T":"[\\u0422\\u0442]","U":"[\\u0423\\u0443]","F":"[\\u0424\\u0444]","H":"[\\u0425\\u0445]","TS":"[\\u0426\\u0446]","CH":"[\\u0427\\u0447]","SH":"[\\u0428\\u0448\\u0429\\u0449]","I":"[\\u042B\\u044B]","E":"[\\u042D\\u044D]","YU":"[\\u042E\\u044E]","YA":"[\\u042F\\u044F]","N":"[\\u041D\\u043D]"},"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasRedirection":true,"hasBreadcrumb":true},"homeUrl":"https:\/\/medicalpointinternational.com\/ru\/","objectID":16065,"objectType":"post","locale":"ru","localeFull":"ru_RU","overlayImages":{"play":{"name":"Play \u0438\u043a\u043e\u043d\u043a\u0430","url":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","path":"\/home\/medicalpointint\/public_html\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","position":"middle_center"},"gif":{"name":"GIF \u0438\u043a\u043e\u043d\u043a\u0430","url":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","path":"\/home\/medicalpointint\/public_html\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","position":"middle_center"}},"defautOgImage":"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2024\/12\/Medical-Point-International-Hospital-Empty-Pic.png","customPermalinks":true,"isUserRegistered":true,"autoSuggestKeywords":true,"connectSiteUrl":"https:\/\/rankmath.com\/auth?site=https%3A%2F%2Fmedicalpointinternational.com%2Fru%2F&r=https%3A%2F%2Fmedicalpointinternational.com%2Fru%2Fwp-json%2Fwp%2Fv2%2Fpages%2F16065%3Fnonce%3De7ae5d2bf7&pro=1","maxTags":100,"trendsIcon":"<svg viewBox=\"0 0 610 610\"><path d=\"M18.85,446,174.32,290.48l58.08,58.08L76.93,504a14.54,14.54,0,0,1-20.55,0L18.83,466.48a14.54,14.54,0,0,1,0-20.55Z\" style=\"fill:#4285f4\"\/><path d=\"M242.65,242.66,377.59,377.6l-47.75,47.75a14.54,14.54,0,0,1-20.55,0L174.37,290.43l47.75-47.75A14.52,14.52,0,0,1,242.65,242.66Z\" style=\"fill:#ea4335\"\/><polygon points=\"319.53 319.53 479.26 159.8 537.34 217.88 377.61 377.62 319.53 319.53\" style=\"fill:#fabb05\"\/><path d=\"M594.26,262.73V118.61h0a16.94,16.94,0,0,0-16.94-16.94H433.2a16.94,16.94,0,0,0-12,28.92L565.34,274.71h0a16.94,16.94,0,0,0,28.92-12Z\" style=\"fill:#34a853\"\/><rect width=\"610\" height=\"610\" style=\"fill:none\"\/><\/svg>","showScore":true,"siteFavIcon":"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2024\/12\/Medical-Point-International-Hospital-Empty-Pic-150x150.png","canUser":{"general":false,"advanced":false,"snippet":false,"social":false,"analysis":false,"analytics":false,"content_ai":false},"showKeywordIntent":true,"isPro":true,"is_front_page":false,"trendsUpgradeLink":"https:\/\/rankmath.com\/pricing\/?utm_source=Plugin&utm_medium=CE%20General%20Tab%20Trends&utm_campaign=WP","trendsUpgradeLabel":"\u0410\u043f\u0433\u0440\u0435\u0439\u0434","trendsPreviewImage":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/trends-preview.jpg","currentEditor":false,"homepageData":{"assessor":{"powerWords":[],"diacritics":true,"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasBreadcrumb":true,"serpData":{"title":"%sitename% %page% %sep% %sitedesc%","description":"","titleTemplate":"%sitename% %page% %sep% %sitedesc%","descriptionTemplate":"","focusKeywords":"","breadcrumbTitle":"\u0413\u043b\u0430\u0432\u043d\u0430\u044f","robots":{"index":true},"advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":""}}},"isAnalyticsConnected":false,"tocTitle":"Table of Contents","tocExcludeHeadings":[],"listStyle":"ul"},"_links":{"self":[{"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages\/16065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/comments?post=16065"}],"version-history":[{"count":17,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages\/16065\/revisions"}],"predecessor-version":[{"id":77021,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages\/16065\/revisions\/77021"}],"up":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/pages\/14364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/media\/16068"}],"wp:attachment":[{"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/media?parent=16065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/categories?post=16065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ru\/wp-json\/wp\/v2\/tags?post=16065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}